{"id":24928,"date":"2022-10-25T16:48:00","date_gmt":"2022-10-25T08:48:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24928"},"modified":"2025-02-02T16:59:10","modified_gmt":"2025-02-02T08:59:10","slug":"bimi-international-medical-to-sell-off-underperforming-subsidiary-chongqing-zhuoda","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24928","title":{"rendered":"BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda"},"content":{"rendered":"\n<p>China-based BIMI International Medical Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIMI:OTCMKTS\">OTCMKTS: BIMI<\/a>), a wholesaler of drugs and healthcare products, has announced plans to sell its wholly-owned distribution subsidiary, Chongqing Zhuoda Pharmaceutical Co., Ltd. The 100% equity stake in Zhuoda will be sold to three individuals in China who had previously sold the company to BIMI. As part of the deal, the 440,000 BIMI shares previously paid to the purchasers to acquire Zhuoda will be returned to BIMI. The transaction is expected to close in Q4 2022.<\/p>\n\n\n\n<p><strong>Rationale Behind the Sale<\/strong><br>In a press release, BIMI described Zhuoda as an underperforming asset. The sale will allow the company to focus on enhancing its core operations and strategic initiatives. BIMI is aiming to expand its US operations and is targeting strategic acquisitions in that market to fuel further growth.<\/p>\n\n\n\n<p><strong>Company Background and Business Lines<\/strong><br>Headquartered in Chongqing and founded in 2000, BIMI\u2019s business lines cover wholesale pharmaceuticals, wholesale medical devices, medical services, and retail pharmacies. The company supplies prescription and over-the-counter (OTC) medicines, traditional Chinese medicines (TCMs), healthcare supplies, and medical consumables to clients including clinics and hospitals. BIMI also operates directly-owned and authorized retail stores.<\/p>\n\n\n\n<p><strong>Future Outlook<\/strong><br>The divestiture of Zhuoda is part of BIMI\u2019s broader strategy to streamline its operations and focus on high-growth opportunities, particularly in the US market. This move underscores the company\u2019s commitment to optimizing its business portfolio and pursuing strategic expansion.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based BIMI International Medical Inc. (OTCMKTS: BIMI), a wholesaler of drugs and healthcare products, has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3494,3495,3496],"class_list":["post-24928","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-bimi-international-medical","tag-otcmkts-bimi","tag-zhuoda-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based BIMI International Medical Inc. (OTCMKTS: BIMI), a wholesaler of drugs and healthcare products, has announced plans to sell its wholly-owned distribution subsidiary, Chongqing Zhuoda Pharmaceutical Co., Ltd. The 100% equity stake in Zhuoda will be sold to three individuals in China who had previously sold the company to BIMI. As part of the deal, the 440,000 BIMI shares previously paid to the purchasers to acquire Zhuoda will be returned to BIMI. The transaction is expected to close in Q4 2022.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24928\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24928\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-25T08:48:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-02T08:59:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24928#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24928\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda\",\"datePublished\":\"2022-10-25T08:48:00+00:00\",\"dateModified\":\"2025-02-02T08:59:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24928\"},\"wordCount\":243,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BIMI International Medical\",\"OTCMKTS: BIMI\",\"Zhuoda Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24928#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24928\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24928\",\"name\":\"BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-25T08:48:00+00:00\",\"dateModified\":\"2025-02-02T08:59:10+00:00\",\"description\":\"China-based BIMI International Medical Inc. (OTCMKTS: BIMI), a wholesaler of drugs and healthcare products, has announced plans to sell its wholly-owned distribution subsidiary, Chongqing Zhuoda Pharmaceutical Co., Ltd. The 100% equity stake in Zhuoda will be sold to three individuals in China who had previously sold the company to BIMI. As part of the deal, the 440,000 BIMI shares previously paid to the purchasers to acquire Zhuoda will be returned to BIMI. The transaction is expected to close in Q4 2022.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24928#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24928\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24928#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda - Insight, China&#039;s Pharmaceutical Industry","description":"China-based BIMI International Medical Inc. (OTCMKTS: BIMI), a wholesaler of drugs and healthcare products, has announced plans to sell its wholly-owned distribution subsidiary, Chongqing Zhuoda Pharmaceutical Co., Ltd. The 100% equity stake in Zhuoda will be sold to three individuals in China who had previously sold the company to BIMI. As part of the deal, the 440,000 BIMI shares previously paid to the purchasers to acquire Zhuoda will be returned to BIMI. The transaction is expected to close in Q4 2022.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24928","og_locale":"en_US","og_type":"article","og_title":"BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24928","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-25T08:48:00+00:00","article_modified_time":"2025-02-02T08:59:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24928#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24928"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda","datePublished":"2022-10-25T08:48:00+00:00","dateModified":"2025-02-02T08:59:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24928"},"wordCount":243,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BIMI International Medical","OTCMKTS: BIMI","Zhuoda Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24928#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24928","url":"https:\/\/flcube.com\/?p=24928","name":"BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-25T08:48:00+00:00","dateModified":"2025-02-02T08:59:10+00:00","description":"China-based BIMI International Medical Inc. (OTCMKTS: BIMI), a wholesaler of drugs and healthcare products, has announced plans to sell its wholly-owned distribution subsidiary, Chongqing Zhuoda Pharmaceutical Co., Ltd. The 100% equity stake in Zhuoda will be sold to three individuals in China who had previously sold the company to BIMI. As part of the deal, the 440,000 BIMI shares previously paid to the purchasers to acquire Zhuoda will be returned to BIMI. The transaction is expected to close in Q4 2022.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24928#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24928"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24928#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24928"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24928\/revisions"}],"predecessor-version":[{"id":24931,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24928\/revisions\/24931"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}